Basit öğe kaydını göster

Efficacy, Safety and Responder Subanalysis of Lenalidomide in Heavily Pretreated, Relapsed/Refractory Patients With Mantle Cell Lymphoma Post-Bortezomib: Phase II MCL-001 "EMERGE" Study

dc.contributor.authorCicero, Sherri
dc.contributor.authorBesisik, Sevgi
dc.contributor.authorZhang, Lei
dc.contributor.authorFu, Tommy
dc.contributor.authorWitzig, Thomas
dc.contributor.authorGoy, Andre
dc.contributor.authorWilliams, Michael E.
dc.contributor.authorDrach, Johannes
dc.contributor.authorRamchandren, Radhakrishnan
dc.date.accessioned2021-03-05T11:55:37Z
dc.date.available2021-03-05T11:55:37Z
dc.identifier.citationGoy A., Williams M. E. , Besisik S., Drach J., Ramchandren R., Zhang L., Cicero S., Fu T., Witzig T., "Efficacy, Safety and Responder Subanalysis of Lenalidomide in Heavily Pretreated, Relapsed/Refractory Patients With Mantle Cell Lymphoma Post-Bortezomib: Phase II MCL-001 "EMERGE" Study", CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.14, 2014
dc.identifier.issn2152-2650
dc.identifier.othervv_1032021
dc.identifier.otherav_aa8c0099-738a-4374-9df8-8181f4f090a1
dc.identifier.urihttp://hdl.handle.net/20.500.12627/113883
dc.identifier.urihttps://doi.org/10.1016/j.clml.2014.06.077
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectHematoloji
dc.subjectOnkoloji
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectHEMATOLOJİ
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleEfficacy, Safety and Responder Subanalysis of Lenalidomide in Heavily Pretreated, Relapsed/Refractory Patients With Mantle Cell Lymphoma Post-Bortezomib: Phase II MCL-001 "EMERGE" Study
dc.typeMakale
dc.relation.journalCLINICAL LYMPHOMA MYELOMA & LEUKEMIA
dc.contributor.departmentHackensack University Medical Center , ,
dc.identifier.volume14
dc.contributor.firstauthorID216675


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster